Lawrie Charles H, Gal Shira, Dunlop Heather M, Pushkaran Beena, Liggins Amanda P, Pulford Karen, Banham Alison H, Pezzella Francesco, Boultwood Jacqueline, Wainscoat James S, Hatton Christian S R, Harris Adrian L
Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Br J Haematol. 2008 May;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. Epub 2008 Mar 3.
Circulating nucleic acids have been shown to have potential as non-invasive diagnostic markers in cancer. We therefore investigated whether microRNAs also have diagnostic utility by comparing levels of tumour-associated MIRN155 (miR-155), MIRN210 (miR-210) and MIRN21 (miR-21) in serum from diffuse large B-cell lymphoma (DLBCL) patients (n = 60) with healthy controls (n = 43). Levels were higher in patient than control sera (P = 0.009, 0.02 and 0.04 respectively). Moreover, high MIRN21 expression was associated with relapse-free survival (P = 0.05). This is the first description of circulating microRNAs and suggests that microRNAs have potential as non-invasive diagnostic markers for DLBCL and possibly other cancers.
循环核酸已被证明有潜力作为癌症的非侵入性诊断标志物。因此，我们通过比较弥漫性大B细胞淋巴瘤（DLBCL）患者（n = 60）和健康对照者（n = 43）血清中肿瘤相关的MIRN155（miR - 155）、MIRN210（miR - 210）和MIRN21（miR - 21）水平，来研究微小RNA是否也具有诊断效用。患者血清中的水平高于对照血清（P值分别为0.009、0.02和0.04）。此外，高MIRN21表达与无复发生存相关（P = 0.05）。这是对循环微小RNA的首次描述，表明微小RNA有潜力作为DLBCL及可能其他癌症的非侵入性诊断标志物。
